With nearly 30 years’ experience of developing accurate assay solutions for diagnosis, prognosis and monitoring treatment we have proven expertise in our focus areas covers several competences.
We prides ourselves on leading on the way in life science, pushing the boundaries in drug development and clinical diagnostics through international cooperation and the sharing of good practice and expertise.
MOVING FROM PROMISE TO REALITY
Gene therapy holds great promise as an effective treatment of these diseases. Over the coming decades, gene therapy treatment of a wide range of disorders, such as inherited diseases, cancer and viral infections, may be commonplace.
The complement system is described as a double-edged sword. If not properly controlled and regulated, the complement system has the potential to harm the host and disturbances in the system is an effector in a large variety of disorders.
Autoimmunity is a condition where the immune system fails to recognize its own cells and tissues as “self”. Instead, immune responses are launched against these cells and tissues as if they were foreign or invading bodies.
Much of the focus in the development of recent gene therapeutic therapies has been on retinal rare diseases, that result from modifications in a single gene. These retinal diseases tend to have clear genomic targets as well as high unmet needs in patient populations and patients.
Antibody-dependent cellular cytotoxicity (ADCC) is a mechanism of cell-mediated immune defense whereby an effector cell of the immune system actively destroys a target cell, whose membrane-surface antigens have been bound by specific antibodies
When done correctly, e-Health has great benefits for the patient, the physicians, hospital, and society as a whole, and can drastically reduce the use of heavy medication, emergency admissions, surgeries, and other expensive treatments.
Traditionally, colony stimulating factors are used in patients who are undergoing cancer treatment that causes low white blood cell counts (neutropenia) and puts the patient at risk of infection. Treatment with CSFs reduces the time where patients are neutropenic.
Interleukins (IL) are a group of naturally occurring proteins that mediate communication between cells. They have a pivotal role in the mediation of the physiological response to infection and contribute significantly to the functional changes that accompany a particular disease or disorder.